Efficiency of Retinoprotective Dry AMD Therapy with Neuroprotective Therapy: a Randomized Clinical Trials Meta-analysis

Article retracted.Рurpose. А meta-analysis of randomized clinical trials of efficiency and safety of retinalamin water-soluble polypeptide retinal fractionscomplex neuroprotective therapy in patients with dry age-related macular degeneration (amd), conducted in russia. Мethods. Published results of...

Full description

Bibliographic Details
Main Authors: V. P. Erichev, S. Yu. Petrov, A. V. Volzhanin
Format: Article
Language:Russian
Published: Ophthalmology Publishing Group 2018-03-01
Series:Oftalʹmologiâ
Subjects:
Online Access:https://www.ophthalmojournal.com/opht/article/view/546
_version_ 1797875512647876608
author V. P. Erichev
S. Yu. Petrov
A. V. Volzhanin
author_facet V. P. Erichev
S. Yu. Petrov
A. V. Volzhanin
author_sort V. P. Erichev
collection DOAJ
description Article retracted.Рurpose. А meta-analysis of randomized clinical trials of efficiency and safety of retinalamin water-soluble polypeptide retinal fractionscomplex neuroprotective therapy in patients with dry age-related macular degeneration (amd), conducted in russia. Мethods. Published results of various clinical trials were searched by a single investigator using the “scientific electronic library” (elibrary.ru). meta-analysis included all clinical trials of retinalamin efficacy, where its route of administration and dosage corresponded with the guidelines for medical use of retinalamin in patients with dry amd. Results. Primary search revealed 320 publications concerning retinalamin. 11 of those presented results of randomized clinical trial that satisfied the requirements, and hence were included into the meta-analysis. beside the parabulbar and intramuscular administration, prescribed officially, retinalamin was also administered subconjunctivally, with electrophoresis and with subcutaneous injections in temporal zone. in three studies the observation period is 3 months, in one study it is 5 months, in four studies it is 6 months, and in two studies it is 12 months. in the rest of studies the observation period is less than 3 months. all the studies present the changes in visual acuity right after the therapy course. meta-analysis revealed a statistically significant visual acuity improvement, best discernible in patients with areds 3 amd stage up to 6 months after retinalamin treatment. the positive dynamics in visual acuity changing persists during the first 3 months. repeatedtherapy courses in 3–6 months provided further progress. perimetry revealed the increasing of visual field borders and decreasingof central scotomae amount and area; the findings have also improved after the repeated course. the electrophysiology studyingshowed the positive dynamics as well and correlated with visual acuity changes. optical coherence tomography, blood flow examination and a series of other tests were also used. however, varying diagnostic methods in different trials as well as a low level of statistical data processing, impeded the fulfillment of a comprehensive analysis. Conclusion. Randomized clinical trial meta-analysis proved the efficacy of retinalamin therapy in patients with dry amd
first_indexed 2024-04-10T01:47:39Z
format Article
id doaj.art-4e5fd440158b43aa8aebace697c1d902
institution Directory Open Access Journal
issn 1816-5095
2500-0845
language Russian
last_indexed 2024-04-10T01:47:39Z
publishDate 2018-03-01
publisher Ophthalmology Publishing Group
record_format Article
series Oftalʹmologiâ
spelling doaj.art-4e5fd440158b43aa8aebace697c1d9022023-03-13T09:08:38ZrusOphthalmology Publishing GroupOftalʹmologiâ1816-50952500-08452018-03-01151697910.18008/1816-5095-2018-1-69-79385Efficiency of Retinoprotective Dry AMD Therapy with Neuroprotective Therapy: a Randomized Clinical Trials Meta-analysisV. P. Erichev0S. Yu. Petrov1A. V. Volzhanin2ФГБНУ «Научно-исследовательский институт глазных болезнейФГБНУ «Научно-исследовательский институт глазных болезнейФГБНУ «Научно-исследовательский институт глазных болезнейArticle retracted.Рurpose. А meta-analysis of randomized clinical trials of efficiency and safety of retinalamin water-soluble polypeptide retinal fractionscomplex neuroprotective therapy in patients with dry age-related macular degeneration (amd), conducted in russia. Мethods. Published results of various clinical trials were searched by a single investigator using the “scientific electronic library” (elibrary.ru). meta-analysis included all clinical trials of retinalamin efficacy, where its route of administration and dosage corresponded with the guidelines for medical use of retinalamin in patients with dry amd. Results. Primary search revealed 320 publications concerning retinalamin. 11 of those presented results of randomized clinical trial that satisfied the requirements, and hence were included into the meta-analysis. beside the parabulbar and intramuscular administration, prescribed officially, retinalamin was also administered subconjunctivally, with electrophoresis and with subcutaneous injections in temporal zone. in three studies the observation period is 3 months, in one study it is 5 months, in four studies it is 6 months, and in two studies it is 12 months. in the rest of studies the observation period is less than 3 months. all the studies present the changes in visual acuity right after the therapy course. meta-analysis revealed a statistically significant visual acuity improvement, best discernible in patients with areds 3 amd stage up to 6 months after retinalamin treatment. the positive dynamics in visual acuity changing persists during the first 3 months. repeatedtherapy courses in 3–6 months provided further progress. perimetry revealed the increasing of visual field borders and decreasingof central scotomae amount and area; the findings have also improved after the repeated course. the electrophysiology studyingshowed the positive dynamics as well and correlated with visual acuity changes. optical coherence tomography, blood flow examination and a series of other tests were also used. however, varying diagnostic methods in different trials as well as a low level of statistical data processing, impeded the fulfillment of a comprehensive analysis. Conclusion. Randomized clinical trial meta-analysis proved the efficacy of retinalamin therapy in patients with dry amdhttps://www.ophthalmojournal.com/opht/article/view/546метаанализвозрастная макулярная дегенерацияретиналамин
spellingShingle V. P. Erichev
S. Yu. Petrov
A. V. Volzhanin
Efficiency of Retinoprotective Dry AMD Therapy with Neuroprotective Therapy: a Randomized Clinical Trials Meta-analysis
Oftalʹmologiâ
метаанализ
возрастная макулярная дегенерация
ретиналамин
title Efficiency of Retinoprotective Dry AMD Therapy with Neuroprotective Therapy: a Randomized Clinical Trials Meta-analysis
title_full Efficiency of Retinoprotective Dry AMD Therapy with Neuroprotective Therapy: a Randomized Clinical Trials Meta-analysis
title_fullStr Efficiency of Retinoprotective Dry AMD Therapy with Neuroprotective Therapy: a Randomized Clinical Trials Meta-analysis
title_full_unstemmed Efficiency of Retinoprotective Dry AMD Therapy with Neuroprotective Therapy: a Randomized Clinical Trials Meta-analysis
title_short Efficiency of Retinoprotective Dry AMD Therapy with Neuroprotective Therapy: a Randomized Clinical Trials Meta-analysis
title_sort efficiency of retinoprotective dry amd therapy with neuroprotective therapy a randomized clinical trials meta analysis
topic метаанализ
возрастная макулярная дегенерация
ретиналамин
url https://www.ophthalmojournal.com/opht/article/view/546
work_keys_str_mv AT vperichev efficiencyofretinoprotectivedryamdtherapywithneuroprotectivetherapyarandomizedclinicaltrialsmetaanalysis
AT syupetrov efficiencyofretinoprotectivedryamdtherapywithneuroprotectivetherapyarandomizedclinicaltrialsmetaanalysis
AT avvolzhanin efficiencyofretinoprotectivedryamdtherapywithneuroprotectivetherapyarandomizedclinicaltrialsmetaanalysis